SCHEMBL20354564

SCHEMBL20354564

CN(C)C1(C)CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.53
ALDH1A1 P00352 7/20 0.53
GAA P10253 6/20 0.53
GFER P55789 5/20 0.53
KDM4E B2RXH2 4/20 0.53
KMT2A Q03164 2/20 0.53
PTK2B Q14289 2/20 0.53
ADRA2C P18825 1/20 0.53
ESR2 Q92731 1/20 0.53
HTT P42858 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
RECQL P46063 2/20 0.50
TP53 P04637 2/20 0.50
ALOX15 P16050 2/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
USP2 O75604 1/20 0.50
POLB P06746 1/20 0.50
THRB P10828 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24123778 0.83 ADRB1 (0.50) MAPTALDH1A1GAAKDM4EKMT2A
SCHEMBL18937140 0.82 MAPT (0.59) MAPTALDH1A1GAAGFERKDM4E
SCHEMBL13724583 0.79 MAPT (0.55) MAPTALDH1A1GAAGFERKDM4E
SCHEMBL25675659 0.79 HSD11B1 (0.46) MAPTALDH1A1GAAKDM4EHTT
SCHEMBL21526576 0.76 SIRT6 (0.61) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL29225028 0.76 GFER (0.46) MAPTALDH1A1GAAGFERKDM4E
SCHEMBL22465998 0.76 MAPT (0.50) MAPTALDH1A1GAAGFERKDM4E
SCHEMBL14320742 0.76 MAPT (0.60) MAPTALDH1A1GAAGFERKDM4E
SCHEMBL7043679 0.75 MAPT (0.77) MAPTALDH1A1GAAGFERKDM4E
SCHEMBL6151120 0.75 MAPT (0.77) MAPTALDH1A1GAAGFERKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564232-B1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2022-01-26 EP disclosed
EP-3564232-B1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2022-01-26 EP disclosed
US-10954216-B2 BMP-signal-inhibiting compound RIKEN (JP) 2021-03-23 US disclosed
US-10954216-B2 BMP-signal-inhibiting compound RIKEN (JP) 2021-03-23 US disclosed
US-20190337926-A1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2019-11-07 US disclosed
US-20190337926-A1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2019-11-07 US disclosed
EP-3564232-A1 BMP-SIGNAL-INHIBITING COMPOUND Riken (JP) 2019-11-06 EP disclosed
WO-2018124001-A1 BMP-SIGNAL-INHIBITING COMPOUND 国立研究開発法人理化学研究所 2018-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954216-B2 BMP-signal-inhibiting compound BMP1, BMP2, BMP4 MAPT 4782/4885ALDH1A1 4324/4885GAA 1928/4885
US-20190337926-A1 BMP-SIGNAL-INHIBITING COMPOUND BMP1, BMP2, BMPR2 MAPT 4243/4885ALDH1A1 4102/4885GAA 1552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.